Omeprazol Laboratórios Azevedos (Omeprazole Sodium)

Omeprazole, the active ingredient in Omeprazol Laboratórios Azevedos, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Omeprazol Laboratórios Azevedos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazol Laboratórios Azevedos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders:

- Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSAID‑associated ulcer prevention: lowers the risk of ulcer formation in patients requiring long‑term non‑steroidal anti‑inflammatory drug therapy.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually transient. - Nausea or abdominal discomfort: occasional. - Flatulence: mild bloating. - Constipation: infrequent. - Dry mouth: occasional.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: renal inflammation. - Hypomagnesemia: low serum magnesium levels. - Osteoporotic fractures: increased risk with long‑term use. - Severe cutaneous adverse reactions: such as Stevens‑Johnson syndrome. - Anaphylaxis: rare systemic allergic reaction.

Omeprazole should be used with consideration of patient‑specific factors and proper handling.

- Assess renal and hepatic function: adjust use if impairment is present. - Review concomitant medications: potential for altered absorption or interaction. - Limit duration of therapy: avoid unnecessary long‑term use. - Monitor for vitamin B12 deficiency: especially with prolonged treatment. - Counsel on potential rebound acid hypersecretion after discontinuation. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir and other protease inhibitors: decreased absorption, loss of antiviral efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation parameters. - Methotrexate: reduced renal clearance, watch for toxicity. - Digoxin: increased serum concentrations, assess cardiac status. - Diazepam: elevated levels may cause sedation, adjust dose if needed. - Iron supplements: reduced absorption, separate dosing times.